Review Article
Cellular retinoic acid bioavailability in various pathologies and its therapeutic implication
Makoto Osanai,
Corresponding Author
Makoto Osanai
Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
Correspondence: Makoto Osanai, MD, PhD, Department of Pathology, Sapporo Medical University School of Medicine, South-1, West-17, Chuo-ku, Sapporo 060-8556, Japan. Email: [email protected]
Search for more papers by this authorMakoto Osanai,
Corresponding Author
Makoto Osanai
Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan
Correspondence: Makoto Osanai, MD, PhD, Department of Pathology, Sapporo Medical University School of Medicine, South-1, West-17, Chuo-ku, Sapporo 060-8556, Japan. Email: [email protected]
Search for more papers by this authorAbstract
Retinoic acid (RA), an active metabolite of vitamin A, is a critical signaling molecule in various cell types. We found that RA depletion caused by expression of the RA-metabolizing enzyme CYP26A1 promotes carcinogenesis, implicating CYP26A1 as a candidate oncogene. Several studies of CYP26s have suggested that the biological effect of RA on target cells is primarily determined by “cellular RA bioavailability”, which is defined as the RA level in an individual cell, rather than by the serum concentration of RA. Consistently, stellate cells store approximately 80% of vitamin A in the body, and the state of cellular RA bioavailability regulates their function. Based on the similarities between stellate cells and astrocytes, we demonstrated that retinal astrocytes regulate tight junction-based endothelial integrity in a paracrine manner. Since diabetic retinopathy is characterized by increased vascular permeability in its early pathogenesis, RA normalized retinal astrocytes that are compromised in diabetes, resulting in suppression of vascular leakiness. RA also attenuated the loss of the epithelial barrier in murine experimental colitis. The concept of “cellular RA bioavailability” in various diseases will be directed at understanding various pathologies caused by RA insufficiency, implying the potential feasibility of a therapeutic strategy targeting the stellate cell system.
REFERENCES
- 1 Durston AJ, Timmermans JP, Hage WJ et al. Nature 1989; 340: 140–44.
- 2 Kastner P, Mark M, Chambon P. Nonsteroid nuclear receptors: What are genetic studies telling us about their role in real life? Cell 1995; 83: 859–69.
- 3 Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 83: 841–50.
- 4 de Thé H. Altered retinoic acid receptor. FASEB J 1996; 10: 955–60.
- 5 Wolbach SB, Howe PR. Tissue changes following deprivation of fat-soluble A vitamin. J Exp Med 1925; 42: 753–77.
- 6 White JA, Beckett-Jones B, Guo YD et al. cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450. J Biol Chem 1997; 272: 18538–41.
- 7 Abu-Abed S, Dolle P, Metzger D et al. The retinoic acid-metabolizing enzyme, CYP26A1, is essential for normal hindbrain patterning, vertebral identity, and development of posterior structures. Genes Dev 2001; 15: 226–40.
- 8 Van heusden J, Wouters W, Ramaekers FC et al. The antiproliferative activity of all-trans-retinoic acid catabolites and isomers is differentially modulated by liarozole-fumarate in MCF-7 human breast cancer cells. Br J Cancer 1998; 77: 1229–35.
- 9 Sonneveld E, van den Brink CE, van der Leede BM et al. Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells. Cell Growth Diff 1998; 9: 629–37.
- 10 Klaassen I, Brakenhoff RH, Smeets SJ et al. Metabolism and growth inhibition of four retinoids in head and neck squamous normal and malignant cells. Br J Cancer 2001; 85: 630–35.
- 11 Ozpolat B, Mehta K, Tari AM et al. G. All-trans-retinoic acid-induced expression and regulation of retinoic acid 4-hydroxylase (CYP26) in human promyelocytic leukemia. Am J Hematol 2002; 70: 39–47.
- 12 Shelton DN, Sandoval IT, Eisinger A et al. Up-regulation of CYP26A1 in adenomatous polyposis coli-deficient vertebrates via a WNT-dependent mechanism: Implications for intestinal cell differentiation and colon tumor development. Cancer Res 2006; 66: 7571–7.
- 13 Osanai M, Lee GH. Increased expression of the retinoic acid-metabolizing enzyme CYP26A1 during the progression of cervical squamous neoplasia and head and neck cancer. BMC Res Notes 2014; 7: 697.
- 14 Osanai M, Sawada N, Lee GH. Oncogenic and cell survival properties of the retinoic acid metabolizing enzyme, CYP26A1. Oncogene 2010; 29: 1135–44.
- 15 French AL, Kirstein LM, Massad LS et al. Association of vitamin A deficiency with cervical squamous intraepithelial lesions in human immunodeficiency virus-infected women. J Infect Dis 2000; 182: 1084–9.
- 16 Wang Z, Boudjelal M, Kang S et al. Ultraviolet irradiation of human skin causes functional vitamin A deficiency, preventable by all-trans retinoic acid pre-treatment. Nat Med 1999; 5: 418–22.
- 17 Osanai M, Petkovich M. Expression of the retinoic acid metabolizing enzyme, CYP26A1 limits programmed cell death. Mol Pharmacol 2005; 67: 1808–17.
- 18 Osanai M, Lee GH. The retinoic acid-metabolizing enzyme CYP26A1 upregulates fascin and promotes the malignant behavior of breast carcinoma cells. Oncol Rep 2015; 34: 850−58.
- 19 Nagata C, Mizoue T, Tanaka K et al. Tobacco smoking and breast cancer risk: An evaluation based on a systematic review of epidemiological evidence among the Japanese population; research group for the development and evaluation of cancer prevention strategies in Japan. Jpn J Clin Oncol 2006; 36: 387–94.
- 20 Baron JA, La Vecchia C, Levi F. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol 1990; 162: 502–14.
- 21 Osanai M, Lee GH. Nicotine-mediated suppression of the retinoic acid-metabolizing enzyme CYP26A1 limits the oncogenic potential of breast cancer. Cancer Sci 2011; 102: 1158−63.
- 22 Osanai M, Lee GH. Enhanced expression of retinoic acid metabolizing enzyme CYP26A1 in sunlight-damaged human skin. Med Mol Morphol 2011; 44: 200−06.
- 23 Osanai M, Lee GH. Elevated expression of the retinoic acid-metabolizing enzyme CYP26C1 in primary breast carcinomas. Med Mol Morphol 2016; 49: 22−7.
- 24 Wake K. Perisinusoidal stellate cells (fat-storing cell, interstitial cells, lipocytes), their related structure in and around the liver sinusoids, and vitamin A-storing cells in extrahepatic organs. Int Rev Cytol 1980; 66: 303–53.
- 25 Senoo H Senoo H, Yoshikawa K, Morii M et al. Hepatic stellate cell (vitamin A-storing cell) and its relative–past, present and future. Cell Biol Int 2010; 34: 1247–72.
- 26 Nishikiori N, Osanai M, Chiba H et al. Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy. Diabetes 2007; 56: 1333–30.
- 27 Osanai M, Nishikiori N, Lee GH et al. Emerging novel treatment strategies for diabetic eye diseases. Curr Diabetes Rev 2010; 6: 35–41.
- 28 Hinz B. Mechanical aspects of lung fibrosis: A spotlight on the myofibroblast. Proc Am Thorac Soc 2012; 9: 137–47.
- 29 Nagy NE, Holven KB, Roos N et al. Storage of vitamin A in extrahepatic stellate cells in normal rats. J Lipid Res 1997; 38: 645–58.
- 30Pancreas star alliance [homepage on the internet]. Available from: http://www.pancreaticstaralliance.com/?p=description
- 31 Sawada N. Tight junction-related human diseases. Pathol Int 2013; 63: 1–12.
- 32 Sawada N, Murata M, Kikuchi K et al. Tight junctions and human diseases. Med Electron Microsc 2003; 36: 147−56.
- 33 Chiba H, Osanai M, Murata M et al. Transmembrane proteins of tight junctions. Biochem Biophys Acta 2008; 1778: 588−600.
- 34 Tsukita S, Furuse M, Itoh M. Structural and signalling molecules come together at tight junctions. Curr Opin Cell Biol 1999; 11: 628–33.
- 35 Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001; 2: 285–93.
- 36 Matter K, Balda MS. Signalling to and from tight junctions. Nat Rev Mol Cell Biol 2003; 4: 225–36.
- 37 Igarashi Y, Utsumi H, Chiba H et al. Glial cell line-derived neurotrophic factor induces barrier function of endothelial cells forming the blood-brain barrier. Biochem Biophys Res Commun 1999; 261: 108–12.
- 38 Igarashi Y, Chiba H, Utsumi H et al. Expression of receptors for glial cell line-derived neurotrophic factor (GDNF) and neurturin in the inner blood-retinal barrier of rats. Cell Struct Funct 2000; 25: 237–41.
- 39 Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480–87.
- 40 Murata T, Nakagawa K, Khalil A et al. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Invest 1996; 74: 819–25.
- 41 Ng EW, Shima DT, Calias P et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discovery 2006; 5: 123–32.
- 42 Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy. Curr Opin Ophthalmol 2004; 15: 508–18.
- 43 Henderson CE, Phillips HS, Pollock RA et al. GDNF: A potent survival factor for motoneurons present in peripheral nerve and muscle. Science 1994; 266: 1062–4.
- 44 Miyajima H, Osanai M, Chiba H et al. Glyceraldehyde-derived advanced glycation end-products preferentially induce VEGF expression and reduce GDNF expression in human astrocytes. Biochem Biophys Res Commun 2005; 330: 361–6.
- 45 Thang SH, Kobayashi M, Matsuoka I. Regulation of glial cell line-derived neurotrophic factor responsiveness in developing rat sympathetic neurons by retinoic acid and bone morphogenetic protein-2. J Neurosci 2000; 20: 2917–25.
- 46 Kubota H, Chiba H, Takakuwa Y et al. Retinoid X receptor alpha and retinoic acid receptor gamma mediate expression of genes encoding tight-junction proteins and barrier function in F9 cells during visceral endoderm differentiation. Exp Cell Res 2001; 263: 163–72.
- 47 Tobioka H, Isomura H, Kokai Y et al. Occludin expression decreases with the progression of human endometrial carcinoma. Hum Pathol 2004; 35: 159–64.
- 48 Osanai M, Takasawa A, Murata M et al. Claudins in cancers – Bench to Bedside. Pflügers Archiv - Eur J Physiol 2017; 469: 55–67.
- 49 Osanai M, Nishikiori N, Murata M et al. Cellular retinoic acid bioavailability determines epithelial integrity: Role of retinoic acid receptor alpha in colitis. Mol Pharmacol 2007; 71: 250−58.
- 50 McCullough FS, Northrop-Clewes CA, Thurnham DI. The effect of vitamin A on epithelial integrity. Proc Nutr Soc 1999; 58: 289–93.
Citing Literature
